SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 12
|
records per page:
next > | last >>
|
|
pages:
1
2
3
4
5
6
...
9
10
11
12
|
presentations:
1 to
50 of
572
|
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
DRUG-DRUG INTERACTIONS IN HIV-ASSOCIATED TB: BALANCING EVIDENCE, RISK, AND PRAGMATISM
(ABSTRACT
1159)
Gary Maartens
University of Cape Town, Cape Town , South Africa
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE
(ABSTRACT
455)
Anthony Podany
University of Nebraska, Omaha, NE, USA
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
EFAVIRENZ PHARMACOKINETICS WITH RIFAMPIN DOUBLE DOSE IN TB-HIV INFECTED PATIENTS
(ABSTRACT
456)
Daniel Warren Atwine
MSF-Epicentre, Mbarara, Uganda
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
PHARMACOKINETICS OF EFAVIRENZ 400MG WITH ISONIAZID/RIFAMPICIN IN PEOPLE WITH HIV
(ABSTRACT
457)
Maddalena Cerrone
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, UK, LONDON, United Kingdom
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
IN SILICO DRUG INTERACTION OF LONG-ACTING RILPIVIRINE AND CABOTEGRAVIR WITH RIFAMPIN
(ABSTRACT
458)
Rajith Kumar Reddy Rajoli
University of Liverpool, Liverpool, Merseyside, United Kingdom
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
THEMED DISCUSSION MODERATOR
Viviana A. Simon
Icahn School of Medicine at Mt Sinai, New York, NY, USA
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
NEF UPREGULATES FASL EARLY WHILE MHCS ARE DOWNREGULATED LATE IN HIV-INFECTED CELLS
(ABSTRACT
186)
Rodrigo Matus-Nicodemos
Vaccine Research Center, NIAID, NIH, Bethesda, USA
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
HIV-1 CORE MORPHOLOGY ASSESSMENT USING SINGLE VIRION IMAGING BASED ON FRET
(ABSTRACT
185)
Anamaria Daniela Sarca
Kyoto University, Kyoto, Kyoto, Japan
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
VISUALISATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CDNA BY CLICK CHEMISTRY
(ABSTRACT
187)
Frauke Christ
Katholieke University Leuven, Leuven, Belgium
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
UBP43 (USP18) ABROGATES INTERFERON AND SAMHD1-MEDIATED RESTRICTION OF HIV-1
(ABSTRACT
189)
Edmund Osei-Kuffour
Heinrich-Heine-University Hospital, Düsseldorf, Germany
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
VPR ENHANCES VIRAL GENE EXPRESSION FROM UNINTEGRATED DNA IN A DCAF1-DEPENDENT MANNER
(ABSTRACT
190)
Sarah B Nodder
Boston University, Boston, MA, USA
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
THEMED DISCUSSION MODERATOR
Adeeba Kamarulzaman
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
HIV DIAGNOSES AMONG PEOPLE WHO INJECT DRUGS - UNITED STATES, 2010–2016
(ABSTRACT
970)
Sheryl Lyss
Centers for Disease Control and Prevention, Atlanta, GA, USA
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
CHARACTERISTICS OF HIV INCIDENT INFECTIONS AMONG PERSONS WHO INJECT DRUGS IN THE US
(ABSTRACT
971)
Christine Agnew-Brune
CDC, Atlanta, GA, USA
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006-2016
(ABSTRACT
973)
Lucia VanOgle Torian
NYC Department of Health and Mental Hygiene, New York, NY, USA
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007-2015
(ABSTRACT
974)
Sarah Lomax Braunstein
New York City Department of Health and Mental Hygiene, Long island city, NY, USA
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
3-YEAR OUTCOMES OF PATIENT NAVIGATION+FINANCIAL INCENTIVES FOR HIV+ SUBSTANCE USERS
(ABSTRACT
975)
Daniel Feaster
University of Miami, Miami, FL, USA
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
THEMED DISCUSSION MODERATOR
Jennifer Jao
Icahn School of Medicine at Mt Sinai, New York, NY, USA
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
LOPINAVIR/RITONAVIR INDUCES MITOCHONDRIAL TOXICITY IN HIV-EXPOSED UNINFECTED CHILDREN
(ABSTRACT
878)
Audrey Monnin
INSERM, Montpellier, France
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
HEU BLOOD MTDNA CONTENT REMAINS ELEVATED FROM BIRTH INTO EARLY LIFE (0-3 YEARS)
(ABSTRACT
879)
Abhinav Ajaykumar
University of British Columbia, Vancouver, BC, Canada
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
INCREASED INFLAMMATION AND MONOCYTE ACTIVATION IN HIV-EXPOSED UNINFECTED INFANTS
(ABSTRACT
880)
Grace A. McComsey
University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
INNATE IMMUNE ACTIVATION AMONG HIV-1 EXPOSED UNINFECTED INFANTS FROM BOTSWANA
(ABSTRACT
881)
Pilar Garcia Broncano
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION, AND GUT DYSBIOSIS IN HIV-EXPOSED INFANTS
(ABSTRACT
882)
Charles DeBeaux Mitchell
University of Miami, Miami, FL, USA
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
THEMED DISCUSSION MODERATOR
Satish Gopal
University of North Carolina Project–Malawi, Lilongwe, Malawi
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
HIV AND CANCER RISK IN CONTEXT OF HIGH ART COVERAGE IN BOTSWANA
(ABSTRACT
649)
Scott Dryden-Peterson
Brigham and Women's Hospital, Boston, MA, USA
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
SOUTH AFRICAN HIV CANCER MATCH STUDY: A PILOT STUDY TOWARDS PRECISION PUBLIC HEALTH
(ABSTRACT
650)
Mazvita Sengayi
National Health Laboratory Services, Johannesburg, South Africa
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN
(ABSTRACT
658)
Michael H. Chung
University of Washington, Seattle, WA, USA
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+
(ABSTRACT
659)
Emmanouil Papasavvas
The Wistar Institute, Philadelphia, USA
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
KNOWLEDGE OF KAPOSI SARCOMA (KS) AND HIV AMONG TRADITIONAL HEALERS IN ZIMBABWE
(ABSTRACT
655)
Suzanne Pressler Fiorillo
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
THEMED DISCUSSION MODERATOR
Linda Chang
University of Maryland, Baltimore, MD, USA
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
CEREBRAL GLUTATHIONE METABOLISM IN ACUTE HIV INFECTION AND RESPONSE TO ART
(ABSTRACT
437)
Napapon Sailasuta
University of Hawaii, Honolulu, HI, USA
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
AMYLOID UPTAKE BY PET IMAGING SUGGEST PREMATURE AGING IN OLDER HIV+ INDIVIDUALS
(ABSTRACT
438)
Ned W Sacktor
Johns Hopkins University, Baltimore, CA, USA
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
NEUROIMAGING CORRELATES OF FRAILTY, COGNITION, AND HIV
(ABSTRACT
439)
Jeremy Strain
Washington University School of Medicine, St. Louis, MO, USA
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
SUBCLINICAL GLOBAL AND THALAMIC HYPOMETABOLISM ON FDG-PET IN TREATED HIV+ SUBJECTS
(ABSTRACT
440)
Dima A. Hammoud
National Institutes of Health, Bethesda, MD, USA
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/R AS FIRST-LINE ART
(ABSTRACT
425)
Ignacio Pérez-Valero
Hospital La Paz, Madrid, Spain
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
THEMED DISCUSSION MODERATOR
Gerardo Garcia-Lerma
Centers for Disease Control and Prevention, Atlanta , GA, USA
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
LOW PREVALENCE OF INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE ACROSS BOTSWANA
(ABSTRACT
542)
Simani Gaseitsiwe
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
HIGH LEVEL RESISTANCE TO DOLUTEGRAVIR (DTG) AFTER EMERGENCE OF T97A MUTATION
(ABSTRACT
543)
Safia S Kuriakose
Leidos Biomedical Research, Inc, Bethesda, MD, USA
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
UNINTEGRATED VIRAL DNA INVOLVED IN DOLUTEGRAVIR RESISTANCE
(ABSTRACT
544)
Olivier Delelis
École Normale Supérieure de Cachan, Cachan, France
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
PREVALENCE AND CLINICAL IMPACT OF MINORITY RESISTANT VARIANTS TO INTEGRASE INHIBITORS
(ABSTRACT
545)
Thuy Thi Thu Nguyen
Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, PARIS, France
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
INTEGRASE INHIBITOR RESISTANCE SELECTIONS INITIATED WITH DRUG RESISTANT HIV-1
(ABSTRACT
546)
Kristen Andreatta
Gilead Sciences, Foster City, CA, USA
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
THEMED DISCUSSION: BONES OF CONTENTION
THEMED DISCUSSION MODERATOR
Eugènia Negredo
Fundació Lluita Contra la Sida, Badalona, Spain
THEMED DISCUSSION: BONES OF CONTENTION
TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY
(ABSTRACT
720)
Gonzague Jourdain
Institut de recherche pour le développement, Chiang Mai, Chiang Mai, Thailand
|
<< first | < prev
page:
of 12
|
records per page:
next > | last >>
|
|
pages:
1
2
3
4
5
6
...
9
10
11
12
|
presentations:
1 to
50 of
572
|
